empagliflozin

Brand names: Synjardy

# Overview of Empagliflozin Empagliflozin is a diabetes medicine that helps control blood sugar levels in people with type 2 diabetes. It works by helping your kidneys remove extra sugar through your urine. This medication is sometimes combined with other diabetes drugs to work better together. Doctors prescribe it to help prevent serious health problems that can happen when blood sugar stays too high, like heart disease and kidney damage. While empagliflozin is helpful for many people, there are some important safety things to know. You should tell your doctor about all medicines you take, especially certain seizure medications like topiramate, because they can affect how your body handles acid levels. Make sure to stay hydrated and watch for unusual symptoms like constant tiredness, trouble breathing, or stomach pain, which could mean serious side effects. Always take this medicine exactly as your doctor prescribes and attend regular check-ups so your doctor can make sure it's working safely for you.

Known Interactions

7 DRUG INTERACTIONS See Table 4 for clinically relevant interactions with SYNJARDY or SYNJARDY XR. Table 4 Clinically Relevant Interactions with SYNJARDY or SYNJARDY XR Carbonic Anhydrase Inhibitors Clinical Impact Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) frequently causes a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with SYNJARDY or SYNJARDY XR may increase the risk of lactic acidosis. Intervention Consider more frequent monitoring of these patients. Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increa

Source: FDA-approved drug labeling via openFDA

Most Reported Side Effects (FAERS)

  • DIABETIC KETOACIDOSIS4,089 reports
  • NAUSEA3,515 reports
  • BLOOD GLUCOSE INCREASED3,409 reports
  • DIARRHOEA3,005 reports
  • WEIGHT DECREASED2,999 reports
  • FATIGUE2,769 reports
  • VOMITING2,641 reports
  • DIZZINESS2,613 reports
  • OFF LABEL USE2,545 reports
  • DRUG INEFFECTIVE2,340 reports

Source: FDA Adverse Event Reporting System (FAERS). Voluntary reports do not establish causation.

Check interactions with empagliflozin:

SafeCheck provides drug interaction information from FDA-approved product labeling (openFDA). This is for informational purposes only and is not medical advice. Always consult your healthcare provider before making medication decisions.